8-K: Panbela Therapeutics Regains Nasdaq Compliance After Meeting Bid Price and Publicly Held Shares Requirements

Panbela Therapeutics has successfully regained compliance with Nasdaq listing standards for bid price and publicly held shares, as confirmed by Nasdaq on February 13, 2024.

Summary

• Panbela Therapeutics has received confirmation from Nasdaq that it has regained compliance with listing standards related to minimum bid price and publicly held shares.
• The company received a letter from Nasdaq on February 13, 2024, confirming the cure of these previously identified deficiencies.
• Panbela will present its equity compliance plan to the Nasdaq Hearings Panel.
• The company's pipeline includes assets in clinical trials focusing on familial adenomatous polyposis (FAP), metastatic pancreatic cancer, and other cancers.
• Ivospemin (SBP-101) has shown promising results in metastatic pancreatic cancer trials, with a median overall survival of 14.6 months and an objective response rate of 48%.
• Flynpovi has demonstrated significant benefit in delaying surgical events for FAP patients with lower GI anatomy in a Phase III trial.
• CPP-1X (eflornithine) is being developed for various indications, including gastric cancer prevention and treatment of neuroblastoma and Type 1 diabetes.

Sentiment

Score: 7

Explanation: The document is generally positive due to the regained Nasdaq compliance and promising clinical trial results. However, the risks associated with drug development and funding are still present.

Positives

• Regaining Nasdaq compliance ensures the company's continued listing on the exchange.
• Ivospemin (SBP-101) has shown promising clinical results in metastatic pancreatic cancer, exceeding typical outcomes with standard treatments.
• Flynpovi has demonstrated a significant benefit in delaying surgical events for FAP patients.
• The company has a diverse pipeline with multiple assets in clinical trials.

Negatives

• The company had previously failed to meet Nasdaq's minimum bid price and publicly held shares requirements.
• Serious visual adverse events have been observed with Ivospemin, requiring exclusion of patients with a history of retinopathy or at risk of retinal detachment from future studies.

Risks

• The company's ability to obtain additional funding is crucial for executing its business and clinical development plans.
• The progress and success of clinical development programs are subject to inherent uncertainties.
• The COVID-19 pandemic could impact the company's ability to conduct clinical trials.
• The company's ability to demonstrate the safety and effectiveness of its product candidates is not guaranteed.
• The company relies on a third party for the execution of the registration trial for Flynpovi.
• Obtaining regulatory approvals for product candidates is subject to regulatory risks.
• Market acceptance and future sales of product candidates are uncertain.
• Changes in regulatory oversight could lead to cost and delays in product development.
• The company faces risks related to establishing reimbursement arrangements with third-party payors.
• The company is subject to the effects of competing technological and market developments.
• The company faces risks related to filing and prosecuting patent applications and enforcing or defending patent claims.
• The company's ability to maintain the listing of its common stock on a national securities exchange is not guaranteed.

Future Outlook

The company plans to continue the development of its pipeline assets, including Ivospemin, Flynpovi, and CPP-1X, with a focus on clinical trials and regulatory approvals. The company will also present its equity compliance plan to the Nasdaq Hearings Panel.

Management Comments

• Panbela has regained compliance with applicable listing standards of The Nasdaq Stock Market for bid price and publicly held shares.
• Nasdaq has issued notice that Panbela has regained compliance for continued listing of its common stock.

Industry Context

This announcement is positive for Panbela as it ensures continued access to capital markets through its Nasdaq listing. The company's focus on developing novel cancer therapeutics aligns with the broader industry trend of seeking innovative treatments for unmet medical needs. The results for Ivospemin are particularly noteworthy as they show a potential improvement over existing standard of care for pancreatic cancer.

Comparison to Industry Standards

• The median overall survival of 14.6 months for Ivospemin in metastatic pancreatic cancer trials is notable, as the standard of care, gemcitabine + nab-paclitaxel, typically shows lower survival rates.
• The objective response rate of 48% for Ivospemin is also higher than what is typically observed with standard chemotherapy regimens for pancreatic cancer.
• Flynpovi's ability to prevent >90% of subsequent pre-cancerous sporadic adenomas versus placebo in a Phase III trial is a significant result, comparing favorably to other preventative treatments for colorectal cancer.
• The statistically significant benefit of Flynpovi in delaying surgical events for FAP patients with lower GI anatomy is a positive outcome, as FAP patients often require multiple surgeries.

Stakeholder Impact

• Shareholders will benefit from the company's continued listing on Nasdaq.
• Patients with unmet medical needs may benefit from the development of new therapeutics.
• Employees will have continued employment opportunities.
• The company's suppliers and creditors will have continued business relationships.

Next Steps

• Panbela will present its equity compliance plan to the Nasdaq Hearings Panel.
• The company will continue the development of its pipeline assets, including Ivospemin, Flynpovi, and CPP-1X.
• The company will focus on clinical trials and regulatory approvals for its product candidates.

Key Dates

Keywords

Nasdaq compliance, Ivospemin, Flynpovi, Panbela Therapeutics, clinical trials, cancer therapeutics, SBP-101, CPP-1X, FAP, pancreatic cancer